The Oral drug delivery market is projected to grow at a CAGR of 6.99% to reach US$ 150.003 billion by 2024. Oral drug delivery is referred to the transfer of drug into the human body through an oral route of administration. This is considered as the most convenient route of administration and is preferred widely among a wide range of consumers. These are in high demand due to the prevalence of chronic diseases worldwide. Furthermore, rising R&D investment, growing health expenditure and a growing geriatric population is further driving the market growth during the forecast period.
Prevalence of Chronic Diseases Worldwide.
Growing Geriatric Population.
Increasing health expenditure worldwide.
Stringent regulations regarding approval of medical devices.
On 27th July, 2017, AstraZeneca and Merck &Co., Inc., announced that they have entered into a global strategic oncology collaboration for the co-development and co-commercialization of AstraZeneca’s Lynparza (olaparib) for multiple cancer types. This is an innovative, first-in-class oral poly ADP ribose polymerase (PARP) inhibitor which is currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment.
In December, 2017, Shire announced its collaboration with Rani Therapeutics for the evaluation of the utilization of the Rani Pill technology for the oral delivery of factor VIII therapy for patients suffering with Hemophilia A.
The major players profiled in the inhalation drug delivery market include Pfizer Inc., AstraZeneca, Alpex Pharma S.A., SPI Pharma, Globela Pharma Pvt Ltd, Lupin Pharmaceuticals, Inc., Bayer AG, and Mayne Pharma Group Limited.
The inhalation drug delivery market has been analyzed through the following segments:
Liquid or Syrup
Middle East and Africa